The PRO-ACT database
Top Cited Papers
- 4 November 2014
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 83 (19), 1719-1725
- https://doi.org/10.1212/wnl.0000000000000951
Abstract
Objective: To pool data from completed amyotrophic lateral sclerosis (ALS) clinical trials and create an open-access resource that enables greater understanding of the phenotype and biology of ALS. Methods: Clinical trials data were pooled from 16 completed phase II/III ALS clinical trials and one observational study. Over 8 million de-identified longitudinally collected data points from over 8,600 individuals with ALS were standardized across trials and merged to create the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. This database includes demographics, family histories, and longitudinal clinical and laboratory data. Mixed effects models were used to describe the rate of disease progression measured by the Revised ALS Functional Rating Scale (ALSFRS-R) and vital capacity (VC). Cox regression models were used to describe survival data. Implementing Bonferroni correction, the critical p value for 15 different tests was p = 0.003. Results: The ALSFRS-R rate of decline was 1.02 (±2.3) points per month and the VC rate of decline was 2.24% of predicted (±6.9) per month. Higher levels of uric acid at trial entry were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.02). Higher levels of creatinine at baseline were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.01). Finally, higher body mass index (BMI) at baseline was associated with longer survival (p < 0.0001). Conclusion: The PRO-ACT database is the largest publicly available repository of merged ALS clinical trials data. We report that baseline levels of creatinine and uric acid, as well as baseline BMI, are strong predictors of disease progression and survival.Keywords
This publication has 40 references indexed in Scilit:
- Biochemical alterations associated with ALSAmyotrophic Lateral Sclerosis, 2011
- ALS clinical trialsNeurology, 2011
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2010
- Oxidative stress in ALS: Key role in motor neuron injury and therapeutic targetFree Radical Biology & Medicine, 2010
- The relationship between uric acid levels and Huntington's disease progressionMovement Disorders, 2010
- Urate as a Predictor of the Rate of Clinical Decline in Parkinson DiseaseArchives of Neurology, 2009
- MRI as an outcome in multiple sclerosis clinical trialsNeurology, 2009
- Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson DiseaseArchives of Neurology, 2008
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotrophic Lateral Sclerosis, 2004
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisThe New England Journal of Medicine, 1994